MétaCan
Menu
← Back to cohort
Record W7019691668

Impact of Clinical and Pharmacogenetic Variables on the Risk of Fluoropyrimidine-Related Adverse Events within Ontario

2021· article· en· W7019691668 on OpenAlexaffabout

Bibliographic record

VenueScholarship@Western (Western University) · 2021
Typearticle
Languageen
FieldMedicine
TopicColorectal Cancer Treatments and Studies
Canadian institutionsWestern University
Fundersnot available
KeywordsAdverse effectPharmacogeneticsAdverse Event Reporting SystemDosingRisk assessmentGenetic testingAdverse drug eventHealth care
DOInot available

Abstract

fetched live from OpenAlex

Severe life-threatening adverse events are a major limitation of fluoropyrimidine chemotherapy, these events are disastrous for patients and costly to the healthcare system. Identifying patients at high risk for developing adverse events would allow for preventive dose reduction, improving patient outcomes and reducing healthcare cost. This thesis uses data pulled from provincial databases to quantify the adverse event burden of fluoropyrimidines in Ontario. We found that 31% of Ontario patients treated with fluoropyrimidine systemic chemotherapy developed a severe adverse event that requires acute medical care. Patients that required acute medical therapy were significantly costlier to the public system averaging an increased cost of $16,754 (CAD). Therefore, there is a substantial potential to reduce cost to the health care system and pay for preventive screening strategies. A known risk factor for fluoropyrimidine adverse events is Dihydropyrimidine dehydrogenase (DPD, gene DPYD) deficiency. We demonstrate that screening for DPD deficiency through targeted genetic testing and genotype-guided dosing reduces the risk of adverse events in genetically deficient patients. Unfortunately, 31% of wildtype patients still experience a severe adverse event, requiring further research into predictors of adverse event risk. Following up on genetic variants, we tested for a recently described intrageneric DPYD deletion through a nested case-control study. We found the deletion associated with toxicity, however the variant was too rare to decide on the overall relevancy to clinical testing at this time. Next, we looked beyond genetics and tested the impact of plasma folate level on adverse event risk. Despite previous literature suggesting an association we found that plasma folate levels were not predictive of fluoropyrimidine adverse event risk. Therefore, there remains a significant number of unexplained fluoropyrimidine-related adverse events. In conclusion, while folate level did not show a predictive value, pharmacogenetic testing was found to be feasible and effective at reducing adverse events. To this end, we worked with Health Quality Ontario to translate these findings, pretreatment DPYD testing is now recommended to be a publicly funded test in Ontario.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.043
Threshold uncertainty score0.124

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.006
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.002
Science and technology studies0.0020.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.110
GPT teacher head0.377
Teacher spread0.267 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueScholarship@Western (Western University)→Same topicColorectal Cancer Treatments and Studies→French-language works237,207→